.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Covington
Baxter
Johnson and Johnson
Moodys
QuintilesIMS
Chubb
Chinese Patent Office
Daiichi Sankyo
Dow

Generated: December 16, 2017

DrugPatentWatch Database Preview

CHANTIX Drug Profile

« Back to Dashboard

Which patents cover Chantix, and what generic alternatives are available?

Chantix is a drug marketed by Pfizer Inc and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and eighty-two patent family members in fifty-six countries and eleven supplementary protection certificates in ten countries.

The generic ingredient in CHANTIX is varenicline tartrate. There are eight drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the varenicline tartrate profile page.
Drug patent expirations by year for CHANTIX

Pharmacology for CHANTIX

Medical Subject Heading (MeSH) Categories for CHANTIX

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer IncCHANTIXvarenicline tartrateTABLET;ORAL021928-001May 10, 2006RXYesNo► Subscribe► SubscribeYY► Subscribe
Pfizer IncCHANTIXvarenicline tartrateTABLET;ORAL021928-001May 10, 2006RXYesNo► Subscribe► Subscribe► Subscribe
Pfizer IncCHANTIXvarenicline tartrateTABLET;ORAL021928-001May 10, 2006RXYesNo► Subscribe► Subscribe► Subscribe
Pfizer IncCHANTIXvarenicline tartrateTABLET;ORAL021928-002May 10, 2006RXYesYes► Subscribe► SubscribeYY► Subscribe
Pfizer IncCHANTIXvarenicline tartrateTABLET;ORAL021928-002May 10, 2006RXYesYes► Subscribe► Subscribe► Subscribe
Pfizer IncCHANTIXvarenicline tartrateTABLET;ORAL021928-001May 10, 2006RXYesNo► Subscribe► SubscribeYY► Subscribe
Pfizer IncCHANTIXvarenicline tartrateTABLET;ORAL021928-001May 10, 2006RXYesNo► Subscribe► SubscribeYY► Subscribe
Pfizer IncCHANTIXvarenicline tartrateTABLET;ORAL021928-001May 10, 2006RXYesNo► Subscribe► Subscribe► Subscribe
Pfizer IncCHANTIXvarenicline tartrateTABLET;ORAL021928-002May 10, 2006RXYesYes► Subscribe► SubscribeYY► Subscribe
Pfizer IncCHANTIXvarenicline tartrateTABLET;ORAL021928-002May 10, 2006RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for CHANTIX

Drugname Dosage Strength RLD Submissiondate
varenicline tartrateTablets0.5 mg and 1 mgChantix5/10/2010

Non-Orange Book Patents for Tradename: CHANTIX

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,605,610 Aryl fused azapolycyclic compounds► Subscribe
7,205,300Aryl fused azapolycyclic compounds► Subscribe
6,951,938 Aryl fused azapolycyclic compounds► Subscribe
7,144,882Aryl fused azapolycyclic compounds► Subscribe
6,897,310 Aryl fused azapolycyclic compounds► Subscribe
6,887,884 Aryl fused azapolycyclic compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: CHANTIX

Country Document Number Estimated Expiration
Serbia51123► Subscribe
Germany60205742► Subscribe
MexicoPA03010364► Subscribe
Luxembourg91442► Subscribe
Australia2874801► Subscribe
Australia2005234671► Subscribe
Eurasian Patent Organization200000592► Subscribe
Austria453643► Subscribe
Slovakia13362003► Subscribe
Germany122008000038► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: CHANTIX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0039France► SubscribePRODUCT NAME: VARENICLINE OU L?UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, NOTAMMENT LE TARTRATE; REGISTRATION NO/DATE IN FRANCE: EU/1/06/360/001 DU 20060926; REGISTRATION NO/DATE AT EEC: EU/1/06/360/001 DU 20060926
C/GB08/034United Kingdom► SubscribePRODUCT NAME: VARENICLINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE TARTRATE SALT; REGISTRATION NO/DATE: EU/1/06/360/001 - 010 20060928
1044189/01Switzerland► SubscribePRODUCT NAME: VARENICLIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57736 21.12.2006
2008010,C1044189Lithuania► SubscribePRODUCT NAME: VARENICLINUM TARTRAT; REGISTRATION NO/DATE: EU/1/06/360/001 - EU/1/06/360/010, 0060926
5Finland► Subscribe
C021/2008Ireland► SubscribeSPC021/2008: 20081105, EXPIRES: 20210925
442Luxembourg► Subscribe91442, EXPIRES: 20210926
2008000038Germany► SubscribePRODUCT NAME: VARENICLIN GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES UNTER EINSCHLUSS VON TARTRAT; REGISTRATION NO/DATE: EU/1/06/360/001-010 20060926
2008 00031Denmark► Subscribe
2008010Lithuania► SubscribePRODUCT NAME: VARENICLINUM TARTRAT; REG. NO/DATE: EU/1/06/360/001-010 20060926
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Covington
UBS
Federal Trade Commission
Johnson and Johnson
Citi
Argus Health
Baxter
Farmers Insurance
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot